Research programme: somatostatin receptor agonists - Crinetics Pharmaceuticals

Drug Profile

Research programme: somatostatin receptor agonists - Crinetics Pharmaceuticals

Alternative Names: CRN 00808

Latest Information Update: 17 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Somatostatin receptor 2 agonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Acromegaly; Neuroendocrine tumours

Most Recent Events

  • 13 Jul 2017 Crinetic Pharmaceuticals receives SBIR grant from National Institute of Diabetes and Digestive and Kidney Diseases for CRN 00808 development in Acromegaly
  • 13 Jul 2017 Crinetics Pharmaceuticals plans clinical trials for CRN 00808 in Acromegaly in the second half of 2017
  • 05 Nov 2015 Early research in Acromegaly in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top